Anti-CD22 Calecheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azatabine in the Treatment of Mixed Phenotype Acute Leukemia: A Case Report
Open Access
- 30 July 2024
- journal article
- letter
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (3) , 202-204
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future DirectionsBioengineering, 2023
- Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?Blood Reviews, 2022
- Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic StrategiesBiomedicines, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALLBlood, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysisHaematologica, 2020
- Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATECancer, 2018
- Survival of patients with mixed phenotype acute leukemias: A large population-based studyLeukemia Research, 2015